Percival S P
Trans Ophthalmol Soc U K (1962). 1985;104 ( Pt 6):616-20.
Analysis of the safety from the use of 1 per cent sodium hyaluronate (Healonid) is presented in terms of postoperative ocular hypertension, uveitis, visual acuity and endothelial cell loss. The results of a four-year clinical trial confirm that this product is safe and effective. There was no significant difference in the short term visual results from its use, however on assessment of comparative endothelial cell studies, it was found that incidences of severe cell loss tend to be excluded by the use of Healonid so improving the surgeons confidence in difficult surgical situations.
从术后眼压升高、葡萄膜炎、视力和内皮细胞损失方面对1%透明质酸钠（Healonid）的使用安全性进行了分析。一项为期四年的临床试验结果证实，该产品安全有效。使用该产品的短期视觉结果无显著差异，然而，在对内皮细胞比较研究进行评估时发现，使用Healonid往往可以排除严重细胞损失的情况，从而提高外科医生在困难手术情况下的信心。
